Sexuality and the menopause.
Sexuality is innate within all women to a greater or lesser extent, and is affected by a number of extrinsic factors that occur in the menopausal transition. Assessing hormone status is difficult as evidence exists that sex hormones may differ between ethnic groups, and that bio-assays may be insensitive at lower testosterone levels. Data are available on the prevalence of female sexual dysfunction, but results from cross-sectional studies differ from those of longitudinal studies. The original traditional models of human sexual response have been challenged, and new models have been defined which show more complex interaction between intrinsic and extrinsic factors. Definitions of sexual dysfunction have been redefined. There are a limited number of randomized, placebo-controlled trials of drugs to improve sexual function. These include sildenafil citrate, tibolone and hormone replacement therapy. Randomized controlled trials on testosterone replacement in naturally and/or surgically menopausal patients with female sexual dysfunction have been criticized for a high placebo response rate and short duration. This chapter seeks to put sexuality into perspective and to define both function and dysfunction.
Pitkin
Joan
J
Northwick Park; St Marks Hospital, N.W. London Hospitals, NHS Trust, Watford Road, HA1 3UJ, UK. Joan.Pitkin@nwlh.nhs.uk
D000328:Adult; D000368:Aged; D000375:Aging / Q000502:physiology; D003430:Cross-Sectional Studies; D005260:Female; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D007989:Libido / Q000187:drug effects / Q000502:physiology*; D008593:Menopause / Q000502:physiology* / Q000523:psychology; D008875:Middle Aged; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D016387:Women's Health